«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

29卷

期数:

2023年06期

页码:

594-598

栏目:

肿瘤研究专题

出版日期:

2023-11-20

文章信息/Info

Title:

Expression of human centromere protein E in human renal clear cell carcinoma and its effects on the cell proliferation

文章编号:

1006-8147(2023) 06-0594-05

作者:

刘芬¹; 李世宾²; 李晓石²

（1.新乡市中心医院，新乡医学院第四临床学院病理科，新乡453000；2.新乡市中心医院，新乡医学院第四临床学院泌尿外科，新乡453000）

Author(s):

LIU Fen¹; LI Shi-bin²; LI Xiao-shi²

（1.Department of Pathology，Xinxiang Central Hospital，The Fourth Clinical College of Xinxiang Medical College，Xinxiang 453000，China；2. Department of Urology，Xinxiang Central Hospital，The Fourth Clinical College of Xinxiang Medical College，Xinxiang 453000，China）

关键词:

人着丝粒蛋白E; 肾透明细胞癌; 免疫组化; 细胞增殖

Keywords:

human centromere protein E; renal clear cell carcinoma;  immunohistochemistry; cell proliferation

分类号:

R737.1

DOI:

-

文献标志码:

A

摘要:

目的：探讨人着丝粒蛋白E（CENPE）在人肾透明细胞癌组织中的表达、临床意义及对细胞增殖的影响。方法：生物信息学分析GEPIA数据库中CENPE在肾透明细胞癌组织及癌旁组织中的mRNA水平，并分析其表达与患者预后之间的关系。回顾性分析来自新乡市中心医院2014年9月—2021年8月接受手术治疗的77例肾透明细胞癌患者的临床病理资料。采用免疫组化法检测肾透明细胞癌组织和癌旁组织中CENPE蛋白表达水平，分析其与患者临床病理特征的关系。培养HTB-47和CRL-1932细胞，通过CENPE的shRNA质粒转染降低其表达，通过集落形成实验及CCK-8实验检测对肾透明细胞癌细胞增殖的影响。结果：生物信息学分析显示肾透明细胞癌患者CENPE显著高表达，并与无病生存期显著相关。免疫组化结果显示CENPE在肾透明细胞癌组织中显著高表达，而在癌旁组织中则为阴性或低表达，表达水平与肿瘤直径显著相关（P=0.021），而与患者的年龄、性别、肿瘤分化无关（均P>0.05）。集落形成实验（P=0.013 5、0.015 4）及CCK-8实验（P=0.009 1、0.013 3）证实CENPE在细胞表达下调并可以抑制肾透明细胞癌细胞的增殖。结论：肾透明细胞癌组织中CENPE显著高表达，且与患者临床病理特征及预后相关，CENPE蛋白促进肾透明细胞癌细胞的增殖。

Abstract:

Objective： To investigate the expression and clinical significance of human centromere protein E（CENPE） in human renal clear cell carcinoma and its effect on cell proliferation. Methods：The mRNA levels of CENPE in renal clear cell carcinoma and para-carcinoma tissues were analyzed in GEPIA database，and the relationship between CENPE expression and prognosis of patients was analyzed. The clinicopathologic data of 77 patients with renal clear cell carcinoma who received surgical treatment from September 2014 to August 2021 at Xinxiang Central Hospital were retrospectively analyzed. Immunohistochemistry was used to detect the expression of CENPE protein in renal clear cell carcinoma and para-carcinoma tissues，and the relationship between CENPE protein expression and clinicopathologic features of patients was analyzed. HTB-47 and CRL-1932 cells were cultured and transfected with shRNA plasmid of CENPE to reduce the expression of HTB-47 and CRL-1932 cells. The effects on the proliferation of renal clear cell carcinoma cells were detected by colony formation assay and CCK-8 assay. Results：Bioinformatics analysis revealed that CENPE was significantly overexpressed in renal clear cell carcinoma patients and was significantly correlated with disease-free survival. Immunohistochemistry revealed significant high expression of CENPE in renal clear cell carcinoma tissues，while negative or low expression in para-carcinoma tissues. The expression level was significantly correlated with tumor size（P=0.021），but not with patient age，sex，or tumor differentiation（all P>0.05）. Colony formation assay（P=0.013 5，0.015 4） and CCK-8 assay（P=0.009 1，0.013 3） confirmed that CENPE down-regulationin cell expression inhibited the proliferation of renal clear cell carcinoma cells. Conclusion：CENPE is highly expressed in renal clear cell carcinoma，which is related to clinicopathological features and prognosis of patients. CENPE protein promotes the proliferation of renal clear cell carcinoma cells.

参考文献/References:

[1] LIU Z，FAN M，HOU J，et al. Serine hydroxymethyltransferase 2 knockdown induces apoptosis in ccRCC by causing lysosomal membrane permeabilization via metabolic reprogramming[J]. Cell Death Dis，2023，14（2）：144.
[2] STONE L. Metabolic flexibility in ccRCC[J]. Nat Rev Urol，2023，20（3）：130.
[3] CHEN J Y，YIU W H，TANG P M，et al. New insights into fibrotic signaling in renal cell carcinoma[J]. Front Cell Dev Biol，2023，11：1056964.
[4] AMENDOLARE A，MARZANO F，PETRUZZELLA V，et al. The underestimated role of the p53 pathway in renal cancer[J]. Cancers （Basel），2022，14（23）：5733.
[5] YOSHIZAWA K，MATSURA A，SHIMADA M，et al. Tetraploidy-linked sensitization to CENP-E inhibition in human cells[J]. Mol Oncol，2023，17（6）：1148-1166.
[6] CILLUFFO D，CHIAVETTA R F，BIVONA S，et al. Transcriptomic changes following partial depletion of CENP-E in normal human fibroblasts[J]. Genes（Basel），2021，12（9）;1322.
[7] EL-ARABEY A A，SALAMA S A，ABD-ALLAH A R. CENP-E as a target for cancer therapy：where are we now?[J].Life Sci，2018，208：192-200.
[8] WENG M T，LEE J H，WEI S C，et al. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells[J]. Proc Natl Acad Sci U S A，2012，109（52）：E3659-E3667.
[9] CHUNG V，HEATH EI，SCHELMAN W R，et al. First-time-in-human study of GSK923295，a novel antimitotic inhibitor of centromere-associated protein E（CENP-E），in patients with refractorycancer[J].Cancer Chemother Pharmacol，2012，69（3）：733-741.
[10] WANG F，ZHAO Q，LIU W，et al. CENPE，PRC1，TTK，and PLK4 may play crucial roles in the osteosarcoma progression[J].Technol Cancer Res Treat，2020，19：1533033820973278.
[11] KUNG P P，MARTINEZ R，ZHU Z，et al. Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer[J]. Mol Cancer Ther，2014，13（8）：2104-2115.
[12] HANNAN R，MCLAUGHLIN M F，POP L M，et al. Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer[J].Eur Urol，2023，84（3）：275-286.
[13] GU D，DONG K，JIANG A，et al. PBRM1 deficiency sensitizes renal cancer cells to DNMT inhibitor 5-fluoro-2′-deoxycytidine[J]. Front Oncol，2022，12：870229.
[14] YU B，CHEN L，ZHANG W，et al. TOP2A and CENPF are synergistic master regulators activated in cervical cancer[J]. BMC Med Genomics，2020，13（1）：145.
[15] LI J，DIAO H，GUAN X，et al. Kinesin family member C1（KIFC1） regulated by centrosome protein E（CENPE） promotes proliferation，migration，and epithelial-mesenchymal transition of ovarian cancer[J]. Med Sci Monit，2020，26：e927869.
[16] SUBRAMONIAN D，CHEN T A，PAOLINI N，et al. Poly-SUMO-2/3 chain modification of Nuf2 facilitates CENP-E kinetochore localization and chromosome congression during mitosis[J].Cell Cycle，2021，20（9）：855-873.
[17] VITRE B，GUDIMCHUK N，BORDA R，et al.Kinetochore-microtubule attachment throughout mitosis potentiated by the elongated stalk of the kinetochore kinesin CENP-E[J]. Mol Biol Cell，2014， 25（15）：2272-2281.
[18] HUANG Y，WANG W，YAO P，et al. CENP-E kinesin interacts with SKAP protein to orchestrate accurate chromosome segregation in mitosis[J]. J Biol Chem，2012，287（2）：1500-1509.

相似文献/References:

[1]魏诗瑶,来佳丹,李常颖.白细胞介素4诱导蛋白1促进肾癌进展的实验研究[J].天津医科大学学报,2022,28(04):366.
　WEI Shi-yao,LAI Jia-dan,LI Chang-ying.Research of interleukin-4-induced-1 promoting the progression of kidney clear cell carcinoma[J].Journal of Tianjin Medical University,2022,28(06):366.
[2]来佳丹,魏诗瑶,李常颖.肾癌来源的IL4I1介导Treg诱导与募集的实验研究[J].天津医科大学学报,2023,29(03):302.
　LAI Jia-dan,WEI Shi-yao,LI Chang-ying.Research on inducement and recruitment of Treg mediated by IL4I1 derived from renal cell carcinoma[J].Journal of Tianjin Medical University,2023,29(06):302.
[3]张春锋,李长建,刘沛,等.KIF22在肾透明细胞癌中的表达及临床相关性研究[J].天津医科大学学报,2023,29(03):309.
　ZHANG Chun-feng,LI Chang-Jian,LIU Pei,et al.Expression and clinical correlation of KIF22 in clear cell renal cell carcinoma[J].Journal of Tianjin Medical University,2023,29(06):309.
[4]李美,来佳丹,魏诗瑶,等.肾透明细胞癌来源的IL4I1介导PD1+CD8+ T淋巴细胞募集的相关研究[J].天津医科大学学报,2024,30(02):122.[doi:10.20135/j.issn.1006-8147.2024.02.0122]
　LI Mei,LAI Jiadan,WEI Shiyao,et al.Research on recruitment of PD1+ CD8+ T lymphocytes mediated by IL4I1 derived from clear cell renal cell carcinoma[J].Journal of Tianjin Medical University,2024,30(06):122.[doi:10.20135/j.issn.1006-8147.2024.02.0122]

备注/Memo

备注/Memo:

作者简介 刘芬（1985-），女，主治医师，硕士，研究方向：肿瘤病理学；通信作者：李晓石，E-mail：lixiaoshi-jj@163.com。

常用功能

更新日期/Last Update: 2023-12-01